Pablo Legorreta: Thanks, Terry. Let's move to Slide 24 for a summary of the key messages you have heard today. First, we delivered solid performance with 3% growth in royalty receipts in 2024, during which we significantly exceeded our initial guidance. We also deployed substantial capital of $2.8 billion as we acquired 8 exciting new royalties, adding further diversification and long-term growth. Second, we continue to have a very attractive opportunity set we conducted initial reviews on over 440 potential royalty transactions, a new record for Royalty Pharma, which speaks both to the fast-growing demand for royalty funding and to our continued leadership position. We did so in a very disciplined manner. In order to drive strong returns, which have trended higher in recent years.